Alembic Pharmaceuticals has announced the incorporation of a wholly owned subsidiary, Alembic Pharmaceuticals GmbH, in Germany. This strategic move aims to explore new business opportunities in the European region, specifically to promote, sell, and distribute pharmaceutical products.
Alembic Pharmaceuticals GmbH has been established with a share capital of EUR 25,000, divided into 25,000 shares, each valued at EUR 1.00. The newly formed entity is yet to commence business operations, and as such, reports a turnover of nil.
The incorporation of Alembic Pharmaceuticals GmbH does not involve any related party transactions, and the promoter or promoter group has no interest in the entity. The company holds 100% shareholding in the newly formed subsidiary.
The pharmaceutical industry, to which the new entity belongs, is expected to benefit from this expansion, as Alembic Pharmaceuticals seeks to strengthen its presence and enhance its market reach in Europe. The company aims to leverage this subsidiary to tap into potential growth opportunities within the region.
No governmental or regulatory approvals were required for this incorporation, and the investment was made in the share capital of the company. There is no indicative time period for the completion of any acquisition, as this announcement pertains solely to the incorporation of the subsidiary.
Alembic Pharmaceuticals is committed to expanding its global footprint and enhancing its capabilities in the pharmaceutical sector through strategic initiatives such as this.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).